Contact Us


What Is Beovu®?

Beovu® is an injectable treatment that can slow the progression of and treat wet age-related macular degeneration. Brolucizumab, brand named Beovu®, is the newest drug to help treat wet AMD. The FDA approved Beovu® in 2019 as another angiogenesis inhibitor. Beovu® joins Eylea®, Lucentis®, and Macugen® as drugs to help inhibit development of abnormal blood vessels. Another drug, Avastin®, has been approved by the FDA to inhibit blood vessel growth in colorectal and other cancers. It has been used off-label to treat wet AMD.